三联激素阻断(ADT3):一个病人的观点

Oncogen Pub Date : 2019-01-30 DOI:10.35702/ONC.10006

C. Maack

{"title":"三联激素阻断(ADT3):一个病人的观点","authors":"C. Maack","doi":"10.35702/ONC.10006","DOIUrl":null,"url":null,"abstract":"Triple-hormonal blockade/androgen deprivation therapy (ADT3) includes the prescribing of a GnRH agonist or antagonist (I use LHRH and GnRH in the following but in reality, either is appropriate for agonists) to shut down testicular testosterone production; an antiandrogen to block testosterone access to the cancer cell nucleus; and a 5Alpha Reductase (5AR) inhibitor to prevent any testosterone that might access the cancer cell nucleus from converting to dihydrotestosterone/DHT. DHT is a 5 times more powerful stimulant than testosterone to prostate cancer cell growth and proliferation.","PeriodicalId":92827,"journal":{"name":"Oncogen","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Triple Hormonal Blockade (ADT3): A Patient’s Perspective\",\"authors\":\"C. Maack\",\"doi\":\"10.35702/ONC.10006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Triple-hormonal blockade/androgen deprivation therapy (ADT3) includes the prescribing of a GnRH agonist or antagonist (I use LHRH and GnRH in the following but in reality, either is appropriate for agonists) to shut down testicular testosterone production; an antiandrogen to block testosterone access to the cancer cell nucleus; and a 5Alpha Reductase (5AR) inhibitor to prevent any testosterone that might access the cancer cell nucleus from converting to dihydrotestosterone/DHT. DHT is a 5 times more powerful stimulant than testosterone to prostate cancer cell growth and proliferation.\",\"PeriodicalId\":92827,\"journal\":{\"name\":\"Oncogen\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncogen\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35702/ONC.10006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncogen","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35702/ONC.10006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

三激素阻断/雄激素剥夺疗法(ADT3)包括GnRH激动剂或拮抗剂的处方(我在以下使用LHRH和GnRH，但实际上，任何一种激动剂都适合)来关闭睾丸睾酮的产生;一种抗雄激素，阻止睾丸激素进入癌细胞细胞核;和5α还原酶(5AR)抑制剂，以防止任何可能进入癌细胞细胞核的睾酮转化为二氢睾酮/二氢睾酮。二氢睾酮对前列腺癌细胞的生长和增殖的刺激作用是睾酮的5倍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Triple Hormonal Blockade (ADT3): A Patient’s Perspective

Triple-hormonal blockade/androgen deprivation therapy (ADT3) includes the prescribing of a GnRH agonist or antagonist (I use LHRH and GnRH in the following but in reality, either is appropriate for agonists) to shut down testicular testosterone production; an antiandrogen to block testosterone access to the cancer cell nucleus; and a 5Alpha Reductase (5AR) inhibitor to prevent any testosterone that might access the cancer cell nucleus from converting to dihydrotestosterone/DHT. DHT is a 5 times more powerful stimulant than testosterone to prostate cancer cell growth and proliferation.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncogen

自引率

0.00%

发文量